Latest News and Press Releases
Want to stay updated on the latest news?
-
Aptose Reports Results for the Second Quarter 2024
-
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
-
Aptose Announces Results from Annual and Special Meeting of Shareholders
-
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
-
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Aptose Reports Results for the First Quarter 2024
-
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
-
Aptose Reports Results for the Fourth Quarter and Full Year 2023
-
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024